Prime Minister David Cameron recently announced an initiative that marks the beginning of a national endeavor to sequence 100,000 genomes in the U.K. National Health Service (NHS). The University of Cambridge will work with Genomics England and Illumina on a three-year project that will sequence 10,000 whole genomes of people with rare genetic diseases to launch this initiative.
"This project will bring enormous improvements to the care of patients with rare genetic diseases. It will shorten the gap between the first signs of ill-health in a person and providing a conclusive diagnosis by using the power of modern DNA sequencing methods," said John Bradley, M.D., director of the NIHR Cambridge Biomedical Research Centre.
The University of Cambridge will work with a team led by David Bentley, Ph.D., vice president and chief scientist at Illumina, to bring routine clinical whole genome sequencing to the bedside in an effort to improve patient care in the U.K. NHS. Illumina will deliver whole genome sequence data for the project using technology invented in Cambridge. The project represents a pilot for Genomics England, which will provide 2,000 samples.
This article was reprinted from Genetic Engineering & Biotechnology News (GEN) with permission from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology News (GEN) has retained its position as the number one biotech publisher around the globe since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, like news and analysis as well as blogs, podcasts, webinars, polls, videos, and application notes. GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.